Porsolt
Porsolt SAS, established in 1985, is a global leader in preclinical research, providing drug discovery, screening, efficacy, and safety services for over 35 years. With a purpose-built laboratory space of over 70,000 sq ft and a team of experienced scientists with decades of expertise from Pharma, Biotech, and CRO environments, Porsolt is committed to scientific excellence, quality, and flexibility. The company offers a wide range of in vitro, in ovo, ex vivo, and in vivo models across various disease areas, supporting all stages of preclinical drug development, including regulatory submissions. Porsolt is GLP compliant, AAALAC accredited, and maintains high standards aligned with international guidelines. The company emphasizes collaborative scientific support, innovative model development, and comprehensive bioanalysis, aiming to advance understanding and treatment of diseases such as oncology, cardiovascular, CNS, dermatology, gastrointestinal, inflammation, metabolic disorders, and more.
Industries
Nr. of Employees
medium (51-250)
Porsolt
Z.A. de Glatigné, 53940 Le Genest-Saint-Isle, France
Services
Design and execution of GLP-compliant in vivo efficacy, safety pharmacology and toxicology studies across multiple species and therapeutic areas.
In vitro toxicology services including cytotoxicity, genotoxicity, organ-specific toxicity panels and time-lapse viability assays to inform safety profiles and regulatory strategies.
Cardiac-safety services including ion-channel assays, cardiomyocyte MEA and calcium assays, ex vivo cardiac tissue testing and in vivo arrhythmia/hemodynamic studies for proarrhythmia and cardiotoxicity evaluation.
ADME/PK study design, multi-route administration, multi-matrix sampling and quantitative bioanalysis to support PK/PD modeling and toxicokinetic assessments.
Tissue processing, histopathology, IHC and multiplex biomarker assays (ELISA, bead-based panels, Western blot, flow cytometry) for mechanistic and endpoint analysis in preclinical studies.
Preclinical evaluation of devices for cytotoxicity, irritation, sensitization, genotoxicity and systemic toxicity aligned with ISO and OECD standards.
Design and execution of GLP-compliant in vivo efficacy, safety pharmacology and toxicology studies across multiple species and therapeutic areas.
In vitro toxicology services including cytotoxicity, genotoxicity, organ-specific toxicity panels and time-lapse viability assays to inform safety profiles and regulatory strategies.
Cardiac-safety services including ion-channel assays, cardiomyocyte MEA and calcium assays, ex vivo cardiac tissue testing and in vivo arrhythmia/hemodynamic studies for proarrhythmia and cardiotoxicity evaluation.
ADME/PK study design, multi-route administration, multi-matrix sampling and quantitative bioanalysis to support PK/PD modeling and toxicokinetic assessments.
Tissue processing, histopathology, IHC and multiplex biomarker assays (ELISA, bead-based panels, Western blot, flow cytometry) for mechanistic and endpoint analysis in preclinical studies.
Preclinical evaluation of devices for cytotoxicity, irritation, sensitization, genotoxicity and systemic toxicity aligned with ISO and OECD standards.
Expertise Areas
- Preclinical CRO services
- In vivo pharmacology and disease modeling
- In vitro pharmacology and high-throughput screening
- Predictive toxicology and GLP safety testing
Key Technologies
- In vivo animal disease models
- Telemetry implants and conscious-animal monitoring
- Ion-channel screening (hERG, Nav, Cav, Kir)
- iPSC-derived cardiomyocytes and neuronal cultures
News & Updates
Introducing Porsolt’s new HPLC system, further enhancing the quality, integrity, reliability, and turnaround times associated with analysis.
Wishing all our friends, collaborators, clients, and their families, a Merry Christmas.
Wishing everyone all the best over the Holiday Season from Porsolt.
The Porsolt team attended SfN in Washington.
October is Breast Cancer Prevention Month and a time to raise awareness.
Porsolt published a recent paper on glioblastoma in Cancers journal.
Introducing Porsolt’s new HPLC system, further enhancing the quality, integrity, reliability, and turnaround times associated with analysis.
Wishing all our friends, collaborators, clients, and their families, a Merry Christmas.
Wishing everyone all the best over the Holiday Season from Porsolt.
The Porsolt team attended SfN in Washington.
October is Breast Cancer Prevention Month and a time to raise awareness.
Porsolt published a recent paper on glioblastoma in Cancers journal.